INSM Insmed Incorporated

Q1 2025 10-Q

Filed: May 8, 2025Period ending Mar 31, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Insmed Incorporated (INSM) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 8, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• No new or updated risk factors disclosed this quarter compared to 10-K filing
• Continued regulatory risk from FDA approval delays impacting product launch timing and revenue realization

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$93M

Net Income

-$257M

Net Margin

-276.4%

Source: XBRL data from Insmed Incorporated Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Insmed Incorporated Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Insmed Incorporated

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.